A new genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs could transform prostate cancer screening by identifying which men are truly at high risk for the disease, allowing doctors to catch cancer earlier while sparing low-risk men from unnecessary procedures. The test analyzes hundreds of genetic changes linked to prostate cancer and costs significantly less than other genome analysis methods, making it practical for large-scale clinical studies. Why Current Prostate Cancer Screening Falls Short For decades, doctors have relied on the prostate-specific antigen (PSA) blood test as the gold standard for prostate cancer screening. But this approach has a major limitation: it's not always reliable. The PSA test can sometimes miss cancer that needs treatment, or it can trigger false alarms that lead to unnecessary biopsies and anxiety. Prostate cancer is the second-leading cause of cancer deaths in U.S. men, making better screening methods critically important. Jason Vassy, a physician-scientist with the VA Boston Healthcare System and Harvard Medical School, recognized that genetics might offer a better answer. "Prostate cancer is one of the most heritable cancers," he explained, meaning family history and genetic factors play a major role in determining who develops the disease. This insight led him and his colleagues to develop a more sophisticated risk prediction tool. How the New P-CARE Model Works The researchers created what they call the P-CARE model (Prostate CAncer integrated Risk Evaluation) by analyzing genetic, family history, and medical data from nearly 600,000 men in the Million Veterans Program, a VA biobank. The model combines three key pieces of information: - Polygenic Score: A calculation based on hundreds of genetic variations across the genome that are linked to prostate cancer risk - Family History: Whether a man's relatives have had prostate cancer, which significantly increases personal risk - Genetic Ancestry: Accounting for how genetic risk factors vary across different populations After validating the P-CARE model in external datasets, the team partnered with Broad Clinical Labs to create a blood test based on this model. Broad Clinical Labs developed a cost-effective method called the "blended genome-exome" that reads the entire genome at several-fold lower cost than other sequencing approaches. What the Clinical Trial Is Revealing The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) is now enrolling 5,000 veterans from across the VA healthcare system nationally. The trial has already enrolled over 3,000 men from every U.S. state and territory. Early results published in Nature Cancer show that the P-CARE model identifies clinically meaningful differences in prostate cancer risk among men. Men predicted to be in the highest-risk group had a several-fold greater chance of being diagnosed with prostate cancer, while those in the lowest-risk group were diagnosed much less often than average. This means the test can effectively separate men who truly need enhanced screening from those who can safely avoid unnecessary procedures. How This Test Could Change Prostate Cancer Care The potential impact of this genetic test extends beyond the VA system. Men deemed high-risk could benefit from enhanced screening to detect cancer earlier, when treatment is most effective. Conversely, men identified as low-risk could avoid unnecessary biopsies and the anxiety that comes with false alarms. "Niall Lennon, chief scientific officer of Broad Clinical Labs, noted that the blended genome-exome is "dollar for dollar one of the best value genetic tests you could get today". The test's low cost makes it feasible for widespread implementation in healthcare systems, not just research settings. This is particularly important because prostate cancer disproportionately affects certain populations, and the P-CARE model was validated in diverse cohorts to ensure it works accurately across different genetic backgrounds. Steps to Understanding Your Prostate Cancer Risk - Talk to Your Doctor: Discuss your family history of prostate cancer and whether genetic testing might be appropriate for you, especially if you have relatives who have had the disease - Consider Your Age and Risk Factors: Prostate cancer primarily affects middle-aged and older men, so timing of screening discussions becomes more relevant as you age - Ask About Genetic Testing Options: As the P-CARE test becomes more widely available, inquire whether your healthcare provider offers this type of precision screening The implications of this research extend beyond individual patient care. "Results from the trial could one day inform care for not only veterans, but for any man looking to evaluate their personal risk level and make informed choices about prostate cancer screening," according to the research team. The study was supported by the U.S. Department of Veterans Affairs Office of Research and Development, National Institutes of Health, Department of Defense, the Prostate Cancer Foundation, the Burroughs Wellcome Foundation, and the Basser Center for BRCA. As genomic medicine advances, precision screening tools like the P-CARE model represent a shift toward personalized healthcare. Instead of applying a one-size-fits-all approach to prostate cancer screening, doctors can now tailor their recommendations based on each man's individual genetic risk profile. This approach promises to improve outcomes while reducing unnecessary medical procedures and the associated costs and anxiety.
